Huddle with Dr. Vish Subramaniam and Dr. Eswar Shankar
Dr. Vish Subramaniam and Dr. Eswar Shankar will introduce us to a promising new non-invasive, non-pharmacological treatment for triple negative breast cancer using induced electric fields.
Eswar ShankarAssistant Research Professor, Ohio State University Comprehensive Cancer Center
Assistant Research Professor. The Ohio State University Comprehensive Cancer Center, Columbus, OH. Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH.
The research focus of Dr. Shankar is on breast and prostate cancer studying the molecular mechanism attributing to initiation and metastasis identifying targets associated with cancer progression and drug resistance. Over the last 14 years Dr. Shankar’s research has evolved in elucidating the mechanisms of oncogenes that orchestrate tumor promotion. In the recent years Dr. Shankar has been involved research to repurpose drugs and come out with combinatorial treatments that synergistically inhibit the growth of metastatic breast cancer. In the current position Dr. Shankar in collaboration with Dr. Bhuvaneswari Ramaswamy, MD, Breast Oncologist, Ohio State University’s Wexner Medical Center and Dr. Vish Subramaniam, Ph.D. Academy Professor, Department of Mechanical & Aerospace Engineering, and OSU Emeritus Academy is developing combinational treatments to inhibit metastasis with minimal or no toxicity to normal cells. He is also involved in applying induced electric field (iEF) technology as a non-pharmacological means of treating metastatic cancer. As evident from his research publications Dr. Shankar has made significant contribution in understanding the molecular signatures altered during this devastating disease. He is funded by the department of defense (DoD)to evaluate the combinatorial effect of dopamine D1 agonist and EZH2 inhibitor GSK126 in arresting triple negative breast cancer progression.
Most recently Dr. Shankar presented how the combinatorial treatment of Dopamine Receptor D1 agonist and EZH2 inhibitor could attenuate Triple Negative Breast cancer progression at a poster session at the San Antonio Breast Cancer Symposium in December of 2022. This work was selected by GRASP advocates and discussed in the advocacy session in December 2022.
Dr. Shankar received is MS from Annamalai University, Tamil Nadu India and completed his Ph.D. from Cochin University of Science and Technology, Kerala, India in Neuroscience.
Vish SubramaniamAcademy Professor and Professor Emeritus, Ohio State University (OSU)
Vish Subramaniam is an Academy Professor and Professor Emeritus in the Department of Mechanical & Aerospace Engineering (MAE) and Professor in the Chemical Physics Program at Ohio State University (OSU).
From 2016 to 2020, he was Professor and Chair of MAE at OSU. He earned his B.S. and M.S. degrees in Mechanical Engineering from Columbia University, and his Ph.D. in Mechanical Engineering from Carnegie Mellon University. Trained in plasma physics, he has been contributing to biophysics for the past decade. His present activities both as an Emeritus faculty member and as the President and CEO of a startup (EMBioSys Inc.) he co-Founded in 2022, are in developing a novel induced electric field (iEF) technology as a non-pharmacological means of treating metastatic cancer.